Join our daily newsletter At The Bell to receive exclusive market insights
- Noxopharm (NOX) publishes preliminary data from its IONIC investigator-initiated pilot trial for its oncology drug Veyonda
- IONIC is exploring Veyonda’s potential to increase the efficiency of Opdivo, an immune inhibitor used to treat solid tumours
- The company completed phase one of the trial, with the findings being published ahead of the American Society of Clinical Oncology’s (ASCO) annual meeting
- Noxopharm is developing its partnerships with researchers to build two new technology platforms, Chroma and Sofra
- Noxopharm last traded at 4.9 cents at 3:15 pm AEST
Biotech company Noxopharm (NOX) has published preliminary data from its IONIC investigator-initiated pilot trial for oncology drug Veyonda.
IONIC is exploring the Veyonda’s potential to increase the activity of Bristol Myers Squibb’s immune checkpoint inhibitor Opdivo (nivolumab) for patients with solid tumours.
Noxopharm’s phase one results will be published in the form of an abstract at the American Society of Clinical Oncology’s (ASCO) annual meeting, which will take place in Chicago in June.
The annual ASCO meeting is one of the largest gathering of oncology professionals, exposing the trial to an array of industry professionals.
Bristol Myers Squibb and Noxopharm completed the trial under a strategic partnership on 30 patients across six sites in Sydney and regional New South Wales.
Noxopharm will continue to develop novel treatments for cancer and inflammation, including the production of new technology to enhance mRNA vaccines.
The company is partnering with leading researchers to build two new technology platforms Chroma (oncology) and Sofra (Inflammation, autoimmunity and mRNA vaccine enhancements) to advance medical technologies.
NOX last traded at 4.9 cents at 3:15 pm AEST.
